CagriSema: Safety Profile Across both pivotal trials, the safety profile of CagriSema was broadly consistent with the established GLP-1 drug class
However, advancements in laser technology have made it an increasingly viable alternative
We revised our regulations at 416.171(a)(2)(iii), (iv), (vi), (vii), and (viii) which establish the annual update to the ASC conversion factor, to reflect this 2-year extension
Unique expression patterns of cell fate molecules delineate sequential stages of dentate gyrus development
Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P